There are two big reasons why Nick Lazaridis decided to join Gene Express as the company’s new president: “One is personalized medicine,” he says, “and the other is their technology.” That technology is the company’s StaRT-PCR platform, currently used by many clinical researchers for analysis of tissue, xenografts, and formalin-fixed paraffin embedded samples.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.